BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 4062320)

  • 1. [Effects of chemotherapy of advanced malignant ovarian tumors].
    Ohta M; Sakakibara K; Casanova H; Nishida Y; Kano T; Tomoda Y; Kazato S; Miyazaki T; Arii Y; Umemura S
    Gan To Kagaku Ryoho; 1985 Nov; 12(11):2208-15. PubMed ID: 4062320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An analysis of factors influential in improving the survival rate of patients with ovarian cancer].
    Ohta M; Tomoda Y; Kano T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1008-15. PubMed ID: 2730004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors].
    Takada M; Usui N; Yoshida K; Hirayama H; Suzuki M; Takeuchi H; Wada H; Iwasa T; Yamamoto T; Nagasawa I
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):333-8. PubMed ID: 2358717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer.
    Cocconi G; DeLisi V; Di Blasio B
    Cancer Treat Rep; 1982 Jun; 66(6):1263-6. PubMed ID: 7083233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metastatic brain tumor after chemotherapy of ovarian cancer].
    Fukuda K; Chen JT; Fujimoto I; Yamauchi K; Hasumi K; Masubuchi K; Sakamoto A
    Gan No Rinsho; 1987 Jan; 33(1):115-8. PubMed ID: 3102810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma].
    Tian WD; Zeng ZY; Chen FJ; Wu GH; Guo ZM; Zhang Q
    Ai Zheng; 2006 Jan; 25(1):80-4. PubMed ID: 16405756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990.
    Venesmaa P
    Obstet Gynecol; 1994 Jul; 84(1):8-11. PubMed ID: 8008329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of advanced ovarian cancer.
    Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
    Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases.
    Low JJ; Perrin LC; Crandon AJ; Hacker NF
    Cancer; 2000 Jul; 89(2):391-8. PubMed ID: 10918171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of advanced ovarian juvenile granulosa cell tumors.
    Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
    Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
    Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Maintenance chemotherapy using UFT and FT for gynecological malignant tumors. The Gunma Prefectural Society for Study of Chemotherapy for Gynecological Cancer].
    Ohwada N; Nagayama M; Kosuge T; Tsukagoshi T; Ibuki Y; Igarashi M; Yazaki K; Ito T; Nogami Y; Kimura H
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2219-26. PubMed ID: 1444488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.